[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"inflammatory-bowel-disease-crohns-disease-ulcerative-colitis\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:inflammatory-bowel-disease-crohns-disease-ulcerative-colitis":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,47,77,100],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":20,"enrollmentInfo":21,"targetDuration":4,"studyType":24,"phases":4,"briefSummary":25,"conditions":26,"keywords":28,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":35,"lastUpdatePostDateStruct":36,"startDateStruct":39,"completionDateStruct":41,"leadSponsor":43,"locationsCount":46},"100649843","tolerogenic-potential-of-hematopoietic-stem-and-progenitor-cells-and-inflammatory-bowel-disease-100649843",false,"NCT07740499","TOLerogenic Potential of Hematopoietic Stem and Progenitor Cells and Inflammatory Bowel Disease","Exploring and Exploiting the TOLerogenic Potential of Hematopoietic Stem and Progenitor Cells to Cure Pediatric Inflammatory Bowel Disease","TOL-IBD","Inclusion Criteria:\n\nFor all groups:\n\n* Written informed consent from parent(s)\u002Flegal guardian(s);\n* Sex: Males and Females;\n* Age: ≥2 years and \\\u003C18 years.\n\nFor study group 1:\n\n\\- Subjects with suspected or confirmed IBD diagnosis.\n\nFor study group 2:\n\n\\- Subjects with rectal bleeding w\u002Fo inflammatory disorders of the gastrointestinal tract.\n\nFor study group 3:\n\n* Written consent for participation to TIGET09 study protocol;\n* healthy subjects, without known immunodeficiencies, autoimmune, inflammatory or genetic diseases, undergoing genetic, hematological, hematochemical, or HLA compatibility screenings and participating in the TIGET09 study protocol (Title: \"Collection of biological samples for the study of blood cells and their microenvironment, and for the development of novel therapeutic approaches for genetic diseases and cancer\").\n\nExclusion Criteria:\n\nFor all groups:\n\n* Refusal or inability of the parent(s) or legal guardian(s) to provide written informed consent;\n* Age: \\\u003C2 years and ≥18 years;\n* Presence of any medical, psychiatric, or clinical condition that, in the opinion of the clinician, may interfere with participation in the study or interpretation of the study results;\n\nFor study group 1:\n\n\\- patients without IBD diagnosis or suspect;\n\nFor study group 2:\n\n\\- Subjects without rectal bleeding or with known inflammatory\u002Fautoimmune disorders of the gastrointestinal tract.\n\nFor all groups:\n\n* Refusal or inability of the parent(s) or legal guardian(s) to provide written informed consent;\n* Age: \\\u003C2 years and ≥18 years;\n* Presence of any medical, psychiatric, or clinical condition that, in the opinion of the clinician, may interfere with participation in the study or interpretation of the study results;\n\nFor study group 1:\n\n\\- patients without IBD diagnosis or suspect;\n\nFor study group 2:\n\n\\- Subjects without rectal bleeding or with known inflammatory\u002Fautoimmune disorders of the gastrointestinal tract.\n\nFor study group 3:\n\n* Lack of written consent for participation to TIGET09 study protocol;\n* patients belonging to study groups 1 and 2; patients with immunodeficiencies, autoimmune, inflammatory or genetic diseases;\n* subjects with signs of systemic inflammation.",true,"ALL","2 Years","18 Years",{"count":22,"type":23},80,"ESTIMATED","OBSERVATIONAL","Pediatric refractory Inflammatory Bowel Disease (IBD) is a chronic inflammatory condition of the gastrointestinal tract, not responsive to current treatments. Since hematopoietic stem and progenitor cells (HSPCs) in the bone marrow display immunomodulatory functions and IL-10-producing regulatory cells regulate gut homeostasis, by combining state-of-the-art strategies for the ex-vivo manipulation and expansion of HSPCs and gene delivery systems to drive HLA-class II-restricted antigen presentation and expression of tolerogenic molecules, the investigators propose to dissect the antigen- (Ag-) presenting capacity of HSPCs and to exploit their tolerogenic potential to induce IL-10-mediated tolerance in the intestinal mucosa of IBD patients. The investigators hypothesize that HSPCs can be engineered using commensal-derived Ags w\u002Fwo IL-10 to drive the differentiation of Tr1 cells with the desired Ag-specificity to control intestinal inflammation in IBD. The results of this study will pave the way for defining innovative cell-based approaches for treating refractory pediatric IBD.",[27],"Inflammatory Bowel Disease (Crohn's Disease; Ulcerative Colitis)",[29,30,31,32,33],"hematopoietic stem and progenitor cells (HSPCs)","immune tolerance","regulatory T cells","IL-10 producing cells","commensal-derived epitopes","NOT_YET_RECRUITING","2026-07-28",{"date":37,"type":38},"2026-07-31","ACTUAL",{"date":40,"type":23},"2026-10",{"date":42,"type":23},"2029-11",{"name":44,"class":45},"IRCCS San Raffaele","OTHER",2,{"id":48,"slug":49,"hasResults":11,"nctId":50,"briefTitle":51,"officialTitle":52,"acronym":4,"eligibilityCriteria":53,"healthyVolunteers":11,"sex":18,"minAge":20,"maxAge":4,"enrollmentInfo":54,"targetDuration":4,"studyType":56,"phases":57,"briefSummary":59,"conditions":60,"keywords":63,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":67,"lastUpdatePostDateStruct":68,"startDateStruct":70,"completionDateStruct":72,"leadSponsor":74,"locationsCount":76},"100644584","online-pain-education-for-crohns-disease-and-ulcerative-colitis-100644584","NCT07671313","Online Pain Education for Crohn's Disease and Ulcerative Colitis","Randomized Controlled Trial of Online Pain Education Programs for Inflammatory Bowel Disease","Inclusion Criteria:\n\n* Physician-confirmed diagnosis of Crohn's disease or ulcerative colitis\n* Chronic pain (visceral and\u002For somatic) related to IBD for at least 3 months\n* NIH PROMIS Pain Interference scale T-score ≥60\n* Medically stable, defined as:\n\n  1. No acute IBD-related hospitalization within the past 3 months; AND\n  2. No planned IBD surgery or planned therapeutic escalation within the next 2 months, including initiation of a new advanced therapy, dose escalation or switch of advanced therapy, or corticosteroid taper\n* Able to understand and complete questionnaires independently in English\n* Access to an internet-enabled device for online surveys and intervention access.\n\nExclusion Criteria:\n\n* Cognitive impairment or other condition that, in the opinion of the investigators, would interfere with protocol participation\n* Current use of standing opioid medications, given the often severe impact of opioids on GI motility and potential for pharmacological visceral hyperalgesia\n* Prior participation in cognitive behavioral therapy (CBT) specifically targeting chronic IBD-related pain",{"count":55,"type":23},60,"INTERVENTIONAL",[58],"NA","Through a pilot randomized controlled trial (RCT), we aim to test the feasibility and preliminary impact of two online pain educations programs among adult patients with inflammatory bowel disease (IBD) who experience chronic pain. Each online program can be accessed on the patient's personal device, and will take about 2 hours to complete. Clinical outcomes (pain intensity, pain interference, quality of life) will be assessed via online surveys at baseline and then weekly for 8-weeks post-treatment.",[61,62,27],"Crohn's Disease","Ulcerative Colitis (UC)",[64,65,66],"Pain Education","Remote Monitoring","Chronic pain","2026-06-22",{"date":69,"type":38},"2026-06-26",{"date":71,"type":23},"2026-08",{"date":73,"type":23},"2027-09",{"name":75,"class":45},"Cedars-Sinai Medical Center",1,{"id":78,"slug":79,"hasResults":11,"nctId":80,"briefTitle":81,"officialTitle":81,"acronym":4,"eligibilityCriteria":82,"healthyVolunteers":11,"sex":18,"minAge":20,"maxAge":4,"enrollmentInfo":83,"targetDuration":4,"studyType":24,"phases":4,"briefSummary":85,"conditions":86,"keywords":88,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":91,"lastUpdatePostDateStruct":92,"startDateStruct":94,"completionDateStruct":96,"leadSponsor":98,"locationsCount":4},"100634997","ai-enhanced-wide-field-endoscopic-fluorescence-mapping-of-gastrointestinal-mucosal-permeability-in-ibd---a-pilot-study-in-ibd-patients-and-controls-100634997","NCT07546955","AI-Enhanced Wide-Field Endoscopic Fluorescence Mapping of Gastrointestinal Mucosal Permeability in IBD - A Pilot Study in IBD Patients and Controls","Inclusion Criteria:\n\n* Adults aged 18 years or older\n* Able to provide written informed consent\n* Established ulcerative colitis or Crohn's disease involving the colon, or non-IBD control undergoing screening\u002Fsurveillance colonoscopy\n* Undergoing clinically indicated colonoscopy\n* Ability to comply with study procedures\n\nExclusion Criteria:\n\n* Allergy to fluorescein\n* Colorectal cancer\n* Advanced polyps or malignant lesions identified during colonoscopy\n* Significant cardiopulmonary disease\n* Renal failure\n* Active infection or sepsis\n* Severe IBD flare\n* Use of medications that may affect gut permeability, including NSAIDs or antibiotics\n* Inability to tolerate bowel preparation or safely complete the protocol\n* Pregnancy or breastfeeding\n* Inability or unwillingness to provide informed consent or comply with study procedures",{"count":84,"type":23},70,"This pilot study will test a new imaging system that uses fluorescent dye and artificial intelligence (AI) during colonoscopy to measure how \"leaky\" the lining of the colon is in people with inflammatory bowel disease (IBD). The study will include 70 adults at 3 Canadian hospitals: 60 people with ulcerative colitis or Crohn's disease affecting the colon, and 10 people without IBD who are having colonoscopy for routine colorectal cancer screening or surveillance. During the colonoscopy, participants will receive intravenous fluorescein, and the imaging system will record fluorescence in the colon as the scope is withdrawn. The main goal is to find out whether this method can be used safely during routine colonoscopy and whether it can produce usable measurements of mucosal permeability. The study will also examine whether these measurements are related to standard measures of inflammation seen during endoscopy, in biopsy samples, and in ex vivo Ussing chamber testing at the McMaster site. The control group will help define what normal fluorescence and permeability look like. This study is intended to provide early data on whether this approach could become a useful new way to assess barrier dysfunction in IBD.",[27,87],"NON-IBD",[89,90],"IBD, CD, UC","Non-IBD","2026-04-17",{"date":93,"type":38},"2026-04-23",{"date":95,"type":23},"2026-04-01",{"date":97,"type":23},"2027-02-01",{"name":99,"class":45},"Hamilton Health Sciences Corporation",{"id":101,"slug":102,"hasResults":11,"nctId":103,"briefTitle":104,"officialTitle":104,"acronym":105,"eligibilityCriteria":106,"healthyVolunteers":11,"sex":18,"minAge":107,"maxAge":108,"enrollmentInfo":109,"targetDuration":4,"studyType":24,"phases":4,"briefSummary":110,"conditions":111,"keywords":112,"overallStatus":114,"whyStopped":4,"lastUpdateSubmitDate":115,"lastUpdatePostDateStruct":116,"startDateStruct":118,"completionDateStruct":120,"leadSponsor":122,"locationsCount":76},"100622455","analysis-of-barriers-and-facilitators-to-adapted-physical-activity-for-pediatric-patients-with-chronic-inflammatory-bowel-diseases-100622455","NCT07383844","Analysis of Barriers and Facilitators to Adapted Physical Activity for Pediatric Patients With Chronic Inflammatory Bowel Diseases","Feels-Mici","Inclusion Criteria:\n\n* Aged 10 to 17 years at inclusion.\n* Diagnosed inflammatory bowel disease (Crohn's disease or ulcerative colitis) confirmed and diagnosed for at least 6 months.\n* Followed in the pediatric gastroenterology department at Hôpital Lenval (CHU de Nice).\n* Sufficient cognitive and language abilities to understand questionnaires and participate in an individual interview.\n* Affiliated to, or beneficiary of, a social security scheme.\n* no parental objection to participation (non-opposition).\n\nExclusion Criteria:\n\n* Younger than 10 years or older than 17 years.\n* No IBD diagnosis, or IBD diagnosed less than 6 months ago.\n* Associated chronic condition (neurological, metabolic, psychiatric, or other) likely to interfere with questionnaire completion or interview participation.\n* Major language or cognitive impairment preventing adequate understanding or interview participation.\n* Not affiliated to, or not beneficiary of, a social security scheme.","10 Years","17 Years",{"count":55,"type":23},"This study aims to identify perceived barriers and facilitators to regular physical activity among children and adolescents with inflammatory bowel disease (IBD) followed in pediatric gastroenterology. Approximately 60 participants aged 10-17 years will complete two self-administered questionnaires (CAPAS-Q for physical activity\u002Fsedentary behavior and IMPACT-III for health-related quality of life) and take part in a single semi-structured interview exploring experiences, obstacles, and levers to support sustainable physical activity. Relevant clinical data (disease characteristics, treatment and selected routine clinical parameters) will be extracted from the medical record. Participation is limited to one visit (about 45-60 minutes) during a routine hospital appointment, with no additional intervention or follow-up required.",[27],[113],"physical activity","RECRUITING","2026-01-26",{"date":117,"type":38},"2026-02-03",{"date":119,"type":38},"2026-01-21",{"date":121,"type":23},"2027-01-31",{"name":123,"class":45},"Fondation Lenval"]